Physician profile
Daniel C Kim
NPI 1124008313
$5,492.61
in general payments reported to CMS, 2019-2025
19 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $250 · 2021: $28.77 · 2023: $489 · 2024: $1,684 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,236 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,235.73 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,284.37 | 2019-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,133.43 | 2019-2025 | Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $547.73 | 2019-2024 | Dupixent |
| Biocryst US Sales Co., LLC | $384.11 | 2023-2025 | Orladeyo |
| Genzyme Corporation | $366.72 | 2020-2025 | |
| Blueprint Medicines Corporation | $270.55 | 2024 | Ayvakit |
| Csl Behring | $232.31 | 2025 | Andembry, Hizentra |
| Lilly USA, LLC | $205.68 | 2019-2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $200.79 | 2025 | Dawnzera |
| Genentech, INC. | $150.00 | 2024 | Xolair |
| Pfizer INC. | $144.90 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $125.00 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2024 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $121.01 | 2019 | |
| Genentech USA, INC. | $76.74 | 2024 | Xolair |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $63.30 | 2019 | |
| Amgen INC. | $34.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Horizon Therapeutics Plc | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.